查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466263

品牌非專利市場：按產品類型、藥物類型、給藥途徑、適應症、分銷管道 - 全球預測 2024-2030

Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年品牌非專利市場規模為4,323億美元，預計2024年將達到4,942.9億美元，2030年將達到11,264.3億美元，複合年成長率為14.66%。

品牌學名藥是指與品牌藥在生物學上等效的藥物，在專利到期後由另一家公司以不同的品牌名稱銷售。這些藥物採用與原廠藥相同的活性成分 (API) 配製，並且必須滿足有關製造流程、安全性和功效標準的類似監管要求。然而，品牌非專利藥與原廠藥在輔料、包裝材料、生產流程等方面可能存在細微差別。消費者對可及治療方法的認知不斷提高、醫療保健成本不斷增加以及重磅藥物專利到期數量的增加正在推動品牌非專利市場的成長。然而，有關藥品核准和品管的嚴格監管要求，以及製造商之間激烈競爭導致的價格下降，可能會阻礙市場成長。然而，藥物研究的進步使得生物等效產品的開發成為可能，為品牌非專利市場的成長創造了有利可圖的機會。

主要市場統計
基準年[2023] 4323億美元
預測年份 [2024] 4942.9億美元
預測年份 [2030] 1,126,430 百萬美元
複合年成長率（%） 14.66%

具有高付加價值的品牌非專利將因其付加的優勢而廣泛採用。

商品非專利是一種將現有學名藥的可靠有效性與知名品牌的認可和聲譽相結合的藥物。這些產品具有學名藥藥和品牌藥的優點，而且價格實惠且品質優良。藥廠通常使用品牌學名藥來進入競爭激烈的市場，為患者提供具有成本效益的替代品，同時保持對醫療工作者的安全性、有效性和可靠性的信心。付加產品是一個透過為消費者提供額外好處而區別於標準配方的類別。這些付加產品可結合多種活性成分以增強治療效果，或採用創新劑型以增加便利性，例如緩釋性或易於吞嚥的錠劑。在某些情況下，具有付加商品名的學名藥，例如 Benitec A（奧美沙群和氨氯地平的組合藥物）、Nifedical（硝苯地平）和Digitech（地高辛），可用於減少副作用或提高患者用藥依從性。

藥物類型高血壓治療中降血壓藥的高使用率

烷化劑是一類主要用於癌症治療的藥物，透過抑制 DNA 複製來限制癌細胞的生長和增殖，例如Cyclophosphamide、Melphalan和順Cisplatin。抗憂鬱症用於治療各種型態的憂鬱症和焦慮症，因為它們可以恢復大腦中神經傳導物質的平衡，特別是血清素、去甲腎上腺素和多巴胺，因此不太常用抗憂鬱症，其中包括Fluoxetine、文拉法辛和阿米替林。抗癲癇藥物 (AED) 是用於預防或控制癲癇患者癲癇發作的藥物。抗高血壓藥物可以降低高血壓患者的血壓，降低心臟病、中風和其他併發症的風險。抗精神病藥物主要用於治療雙極性情感障礙和思覺失調症等精神障礙的症狀。抗代謝藥物是一組化療藥物，可抑制癌細胞中的細胞代謝和 DNA 合成，同時也能模仿 DNA 複製的基本組成部分並抑制參與這些過程的關鍵酵素。荷爾蒙藥物用於治療多種疾病，包括荷爾蒙失衡、內分泌失調和某些癌症。降血脂藥物旨在減少血液中三酸甘油酯和膽固醇的升高，從而減少心臟病等心血管疾病的風險。

給藥途徑：口服給藥因其作用時間長而被廣泛採用。

口服途徑因其方便、易於使用和非侵入性而成為最常見和優選的給藥方法。患者口服錠劑、膠囊和液體型態的品牌學名藥。此外，由於給藥不需要特殊設備或醫療保健專業人員的監督，患者的依從性也得到了提高。腸外給藥採用繞過消化器官系統並將藥物直接輸送到血液的方法。此途徑包括皮下（SC）、肌肉內（IM）和靜脈內（IV）注射和輸注。此途徑對於治療需要快速緩解的病症或口服生物利用度低的藥物特別有益。此外，它們通常比口服給藥更昂貴，因為它們需要專門的設備和無菌製劑。局部給藥涉及將品牌學名藥直接塗布在皮膚或黏膜表面，例如乳膏、凝膠、軟膏或經皮吸收貼片。此途徑允許將藥物局部輸送到目標局部，同時最大限度地減少全身吸收和潛在的副作用。局部給藥的優點包括與全身給藥相比副作用風險降低以及易於使用，從而提高患者的依從性。然而，與局部給藥相關的挑戰包括藥物滲經皮膚屏障的變異性以及應用部位的潛在刺激。

適應症 品牌非專利在胃腸道和神經系統疾病的使用迅速增加

品牌非專利對於提供止痛藥、非類固醇發炎藥 (NSAID) 和鴉片類藥物的選擇至關重要。品牌非專利為高血壓、高血脂症、心臟衰竭和心律不整管理等心血管疾病提供了經濟高效的選擇。痤瘡、真菌感染疾病、濕疹和乾癬等皮膚病是全世界患者廣泛關注的問題。品牌非專利提供了價格實惠的皮膚科治療方法，例如皮質類固醇、類視色素A和抗真菌藥物。發炎性腸道疾病(IBD)、胃食道逆流症 (GERD) 和大腸激躁症(IBS) 等胃腸道疾病可以透過質子幫浦阻斷劑(PPI)、H2 受體拮抗劑和解痙藥等經濟有效的治療非專利進行治療。癲癇、帕金森氏症、多發性硬化症和偏頭痛等神經系統疾病需要負擔得起且有效的治療方法，而品牌非專利藥包括抗癲癇藥 (AED)、多巴胺促效劑和單株抗體，我們正在幫助彌補這一差距。由於創新和分子標靶治療的成本高昂，品牌非專利可能不可行，例如化療、荷爾蒙療法、免疫療法和蛋白酪氨酸激酶抑制劑（TKI）為癌症治療提供了具有成本效益的替代方案。學名藥包括Celebrex（塞來昔布）膠囊、Vascepa（二十碳五烯酸）膠囊、Jublia（艾夫康唑）外用溶液、Asacol HD（美沙拉嗪）錠劑、Abraxane（白蛋白結合型紫杉醇）和Ampyra（達芬吡啶）錠劑都可以使用。

銷售管道管道 不斷發展的品牌非專利線上銷售管道

品牌非專利藥線下分銷管道仍然是患者尋求藥品的首選，這主要是因為其易於獲取並能與醫療專業人員進行即時諮詢。醫院藥局透過確保患者在治療期間獲得負擔得起的藥物，在提供優質醫療保健方面發揮重要作用。醫院藥局越來越喜歡品牌非專利，它們在價格實惠和品質保證之間取得了良好的平衡。這些藥物是按照嚴格的指導方針生產的，並保持與專利藥物相同的高功效。零售藥局是消費者購買藥品的主要場所，為尋求具有成本效益的替代品而不影響品質或功效的消費者創造了品牌非專利的巨大潛力。數位技術的快速進步為線上藥局和電子商務平台成為藥品分銷的重要參與者鋪平了道路。由於線上管道提供的便利性和成本節約（例如詳細的產品資訊、有競爭力的價格和可靠的送貨服務），消費者更喜歡在線購買藥品，品牌非專利在該領域正在蓬勃發展。

區域洞察

由於強大的醫療基礎設施和較高的人均醫藥支出，美洲地區的市場狀況有利。政府努力提高人們對學名藥的認知，這為品牌非專利帶來了光明的成長前景。此外，大型製藥企業對研發的投資導致新產品核准和創新療法進入該市場。歐盟 (EU) 的品牌非專利產業呈現多樣化的景象。隨著歐盟國家醫療保健支出的增加以及各國政府對學名藥實施優惠的定價政策，對具有成本效益的治療方案的需求大幅增加。領先公司正在大力投資研發以開發新藥，同時在新興市場保持與低成本藥物的競爭力。中東和非洲被認為是品牌非專利市場的成長機會，因為政府改善醫療基礎設施和降低藥品價格的努力是擴大市場機會的驅動力。由於研究和開發的活性化、政府的支持措施、對學名藥的需求增加以及國際公司之間為開發創新治療方法以滿足全球需求而進行的合作激增，亞太地區的品牌非專利正在成長，這顯示出巨大的發展潛力。

FPNV定位矩陣

FPNV 定位矩陣對於評估品牌非專利市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對品牌非專利市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估及資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行綜合評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.品牌非專利市場的市場規模與預測為何？

2.品牌非專利市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.品牌非專利市場的技術趨勢和法規結構是什麼？

4.品牌非專利市場主要供應商的市場佔有率為何？

5.進入品牌非專利市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 需要使用學名藥的慢性病的流行
      • 越來越多的重磅藥物專利到期以及對具有成本效益的替代品的需求
    • 抑制因素
      • 對品牌學名藥品質差異的擔憂
    • 機會
      • 透過新的生物等效性研究和市場參與者，努力擴大品牌非專利業務
    • 任務
      • 與訴訟問題和品牌藥價格下跌相關的問題
  • 市場區隔分析
    • 產品：大量採用付加品牌非專利可帶來額外好處
    • 藥物類型： 抗高血壓藥物常用於治療高血壓。
    • 給藥途徑：口服給藥因其作用時間長而被廣泛採用。
    • 適應症：品牌非專利在胃腸道和神經系統疾病的使用激增
    • 分銷管道：品牌非專利線上分銷管道的演變
  • 市場趨勢分析
    • 美洲品牌非專利的結構良好的標準的可用性
    • 亞太地區政府的支持措施和對平價品牌學名藥不斷成長的需求
    • 專注於擴大歐洲、中東和非洲地區品牌非專利地理覆蓋範圍的知名製藥公司的存在
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章 品牌非專利市場：依產品

  • 產品名稱學名藥
  • 付加價值

第7章 品牌非專利藥的類型

  • 烷化劑
  • 抗憂鬱症
  • 抗癲癇藥
  • 抗高血壓
  • 抗精神病藥
  • 抗代謝物
  • 荷爾蒙
  • 降血脂藥

第8章 品牌非專利市場：依管理途徑

  • 口服
  • 胃腸外的
  • 話題

第9章以適應症分類的品牌非專利市場

  • 急性和慢性疼痛
  • 心血管疾病
  • 皮膚病
  • 消化系統疾病
  • 神經系統疾病
  • 腫瘤學

第 10 章 品牌非專利市場：按分銷管道

  • 離線
  • 線上

第11章 美洲品牌非專利市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太品牌非專利市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的品牌非專利市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vyvanse非專利獲 FDA核准
    • 藥聯會與學名藥協會更新學名藥定價協議
    • Amneal 推出經批准的非專利Xyrem（奧昔巴特鈉）並獲得 FDA核准其五種複合非專利
    • Ajanta Pharma 旨在擴大快速成長的亞洲和非洲地區的業務
    • 雷迪博士進軍國內市場學名藥業務
    • Sun Pharma 推出輝瑞重磅抗癌藥物的非專利藥
    • Zentiva 完成西班牙 Tiromed 關鍵產品的收購
    • Cipla推出“Easy Lux L”，一種緩解便秘的無糖口服乳液瀉藥
    • ProCaps Group 從 Advent International 收購 Grupo Somar

第15章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-A26E0E57422E

[194 Pages Report] The Branded Generics Market size was estimated at USD 432.30 billion in 2023 and expected to reach USD 494.29 billion in 2024, at a CAGR 14.66% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts. Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

KEY MARKET STATISTICS
Base Year [2023] USD 432.30 billion
Estimated Year [2024] USD 494.29 billion
Forecast Year [2030] USD 1,126.43 billion
CAGR (%) 14.66%

Product: Significant adoption of value-added branded generics due to their additional advantages

Ttrade-named generics are the pharmaceutical product that combines the trusted efficacy of an established generic drug with the recognition and reputation of a well-known brand name. These products offer the benefits of both generic and branded medicines, with high quality at an affordable price. Pharmaceutical manufacturers commonly use trade-named generics to penetrate competitive markets, providing patients and healthcare professionals with cost-effective alternatives that maintain trust in safety, effectiveness, and reliability. Value-added offerings represent a distinct category that differentiates itself from standard formulations by bringing additional benefits to the consumer. These value-added products may combine multiple active ingredients for enhanced therapeutic effects or adopt innovative dosage forms for improved convenience, such as extended-release formulations or easy-to-swallow tablets. In some cases, value-added trade-named generics can also include drugs reformulated to reduce side effects or improve patient adherence, such as Benitek A (Olmesatran in combination with Amlodipine), Nifedical (nifedipine), and Digitek (digoxin).

Drug Type: High usage of anti-hypertensive for treating high blood pressure

Alkylating agents are a class of drugs primarily used in cancer treatment, and they work by inhibiting DNA replication restricting the growth and multiplication of cancer cells, such as cyclophosphamide, melphalan, and cisplatin. Anti-depressant medications are used to treat various forms of depression and anxiety disorders as they restore the balance of neurotransmitters within the brain, particularly serotonin, norepinephrine, and dopamine, and commonly prescribed anti-depressants include fluoxetine, venlafaxine, and amitriptyline. Anti-epileptic drugs (AEDs) are medications designed to prevent or control epileptic seizures in individuals diagnosed with epilepsy. Anti-hypertensive medications lower blood pressure in individuals with hypertension, reducing the risk of heart disease, stroke, and other complications. Antipsychotic medications are primarily used to manage symptoms of psychotic diseases such as bipolar disorder and schizophrenia. Antimetabolites are a group of chemotherapeutic agents that interfere with cellular metabolism and DNA synthesis in cancer cells while they mimic essential building blocks for DNA replication or inhibit critical enzymes involved in these processes. Hormone-based medications are used in various medical conditions, including hormone imbalances, endocrine disorders, and certain cancers. Lipid-lowering medications are designed to reduce elevated levels of triglyceride and cholesterol in the blood, lowering the chance of cardiovascular disorders such as heart attacks.

Route of Administration: Wide adoption of oral route due to their longer duration of action

The oral route is the most common and preferred method of drug administration due to its convenience, ease of use, and non-invasive nature. Branded generic medications in forms such as tablets, capsules, or liquids are taken orally by the patient. Additionally, they provide higher patient compliance as they do not require specialized equipment or healthcare professional oversight for administration. Parenteral administration involves delivering drugs directly into the bloodstream through means that bypass the digestive system. This route includes subcutaneous (SC), intramuscular (IM), and intravenous (IV) injections and infusions. This route is particularly beneficial when treating conditions requiring quick relief or if a drug has poor oral bioavailability. Additionally, it is generally more expensive than oral administration due to specialized equipment and sterile preparation requirements. Topical administration involves applying branded generic medications directly onto the skin or mucosal surfaces, such as creams, gels, ointments, or transdermal patches. This route allows localized drug delivery to the target site while minimizing systemic absorption and potential side effects. Advantages of topical administration include reduced risk of adverse reactions compared to systemic routes and improved patient compliance due to ease of use. However, challenges associated with topical drug delivery include variability in drug penetration through the skin barrier and the potential for irritation at the application site.

Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases

Branded generics are crucial in providing options for analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. Branded generics offer cost-effective alternatives for cardiovascular diseases such as managing hypertension, hyperlipidemia, heart failure, and arrhythmias. Skin conditions such as acne, fungal infections, eczema, and psoriasis are widespread concerns among patients globally, and branded generics provide affordable access to dermatological treatments, including corticosteroids, retinoids, and antifungal agents. Gastrointestinal diseases such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) require long-term management with medications that are fulfilled by branded generics that offer cost-effective therapies, including proton-pump inhibitors (PPIs), H2 receptor antagonists, and antispasmodics. Neurological disorders such as epilepsy, Parkinson's disease, multiple sclerosis, and migraines demand effective treatments at affordable prices, and branded generics help bridge this gap with anti-epileptic drugs (AEDs), dopaminergic agents, and monoclonal antibodies. Branded generics provide cost-effective alternatives for chemotherapy drugs, hormone therapies, immunotherapies, and tyrosine kinase inhibitors (TKIs) for cancer treatment, as they are perceived as unattainable due to the high costs associated with innovative therapies and targeted agents. Generic versions of Celebrex (celecoxib) capsules, Vascepa (icosapent ethyl) capsules, Jublia (efinaconazole) topical solution, Asacol HD (mesalamine) tablets, Abraxane (nab-paclitaxel), Ampyra (dalfampridine) extended-release tablets are available for treating several diseases.

Distribution Channel: Evolving online distribution channels for branded generics

The offline distribution channel for branded generics remains the first preference for patients seeking medications, primarily due to ease of access and real-time consultation with healthcare professionals. Hospital pharmacies play a vital role in providing quality healthcare by ensuring patients have access to affordable medications during treatment. Hospital pharmacies increasingly favor branded generics as they balance affordability and quality assurance. These drugs are manufactured following strict guidelines and maintain a high efficacy comparable to their patented counterparts. Retail pharmacies serve as a primary source of medications among the general public and create an enormous potential for branded generics as consumers seek cost-effective alternatives without compromising on quality or efficacy. The rapid advancement of digital technologies has paved the way for online pharmacies and eCommerce platforms to emerge as significant players in the pharmaceutical distribution landscape. Branded generics have observed substantial growth in this space due to the convenience and cost savings these online channels provide due to its accessibility of detailed product information, competitive pricing, and reliable delivery services that have led consumers to prefer purchasing their medications online.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector. There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Branded Generics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Branded Generics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Trade Named Generics
    • Value-Added
  • Drug Type
    • Alkylating Agents
    • Anti-depressants
    • Anti-epileptics
    • Anti-hypertensive
    • Anti-psychotics
    • Antimetabolites
    • Hormones
    • Lipid Lowering Drugs
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Indication
    • Acute & Chronic Pain
    • Cardiovascular Diseases
    • Dermatological Diseases
    • Gastrointestinal Diseases
    • Neurological Diseases
    • Oncology
  • Distribution Channel
    • Offline
      • Hospital Pharmacy
      • Retail Pharmacy
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Branded Generics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Branded Generics Market?

3. What are the technology trends and regulatory frameworks in the Branded Generics Market?

4. What is the market share of the leading vendors in the Branded Generics Market?

5. Which modes and strategic moves are suitable for entering the Branded Generics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
      • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with quality variations in branded generic medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
    • 5.1.4. Challenges
      • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
    • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
    • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
    • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
    • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
  • 5.3. Market Trend Analysis
    • 5.3.1. Availability of well-structured standards for branded generics in the Americas
    • 5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
    • 5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Branded Generics Market, by Product

  • 6.1. Introduction
  • 6.2. Trade Named Generics
  • 6.3. Value-Added

7. Branded Generics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Alkylating Agents
  • 7.3. Anti-depressants
  • 7.4. Anti-epileptics
  • 7.5. Anti-hypertensive
  • 7.6. Anti-psychotics
  • 7.7. Antimetabolites
  • 7.8. Hormones
  • 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Branded Generics Market, by Indication

  • 9.1. Introduction
  • 9.2. Acute & Chronic Pain
  • 9.3. Cardiovascular Diseases
  • 9.4. Dermatological Diseases
  • 9.5. Gastrointestinal Diseases
  • 9.6. Neurological Diseases
  • 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
  • 10.3. Online

11. Americas Branded Generics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Branded Generics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Vyvanse Generics Approved by FDA
    • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
    • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
    • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
    • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
    • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
    • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
    • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BRANDED GENERICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 313. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 325. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 326. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 337. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 338. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 349. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 350. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTR